Results 121 to 130 of about 217,331 (294)

Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: Insights from EMPACT‐MI

open access: yesESC Heart Failure, EarlyView.
Impact of empagliflozin in patients with and without T2D or CKD in the EMPACT‐MI trial. Baseline characteristics, HF outcomes and subgroup analysis of efficacy endpoints are shown. # Hazard ratios estimated via Cox proportional hazard model (unless indicated otherwise). ^ Rate ratios via negative binomial regression.
Francesco Fioretti   +23 more
wiley   +1 more source

Progress in Pathogenesis of Proteinuria

open access: yesInternational Journal of Nephrology, 2012
Aims. Proteinuria not only is a sign of kidney damage, but also is involved in the progression of renal diseases as an independent pathologic factor. Clinically, glomerular proteinuria is most commonly observed, which relates to structural and functional
Aihua Zhang, Songming Huang
doaj   +1 more source

SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI

open access: yesESC Heart Failure, EarlyView.
Abstract In the 2021 European Society of Cardiology (ESC) heart failure (HF) guidelines, sodium–glucose cotransporter 2 (SGLT2) inhibitors were recommended for the prevention of HF in patients with type 2 diabetes mellitus (T2DM) and for the treatment of HF with reduced ejection fraction (HFrEF).
Marco Metra   +25 more
wiley   +1 more source

CAQ Corner: Basic concepts of transplant immunology

open access: yes, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

Longest survivor of pulmonary atresia with ventricular septal defect without surgical intervention

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 1499-1507, April 2025.
Sang Zhou   +5 more
wiley   +1 more source

Finerenone in diabetic chronic kidney disease—Real‐world insights including patients with HFpEF or HFmrEF

open access: yesESC Heart Failure, EarlyView.
Abstract Purpose Finerenone, a highly selective non‐steroidal mineralocorticoid receptor antagonist, was approved for the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (diabetic kidney disease, DKD). Finerenone reduced the composite endpoint of heart failure events and cardiovascular death in patients with heart ...
Kristian Hellenkamp   +9 more
wiley   +1 more source

Albuminuria as a diagnostic criterion and a therapeutic target in heart failure and other cardiovascular disease

open access: yesEuropean Journal of Heart Failure, EarlyView.
The value of uACR. CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; uACR, urine albumin‐to‐creatinine ratio. Abstract The high disease burden and bidirectional relationship of chronic kidney disease (CKD), heart failure (HF) and other cardiovascular disease (CVD) necessitate the need for early ...
Biykem Bozkurt   +2 more
wiley   +1 more source

Definition of proteinuria among women with HIV infection [PDF]

open access: bronze, 2004
Lynda A. Szczech   +8 more
openalex   +1 more source

Home - About - Disclaimer - Privacy